Cancer Research Technology
Log in Register
Menu

Anti-CD22, Recombinant [RFB-4]

Invented at University College London

Info

Catalogue Number 152585
Applications FACS IHC IF
Antigen/Gene or Protein Targets CD22
Reactivity Human
Relevance Establishing origin of B cell malignancies, especially discriminating between immature (bone marrow type) and peripheral B cell leukaemias and lymphomas. Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas.
Host Mouse
Immunogen Tonsil lymphocytes
Subclass IgG1
Formulation PBS only
Concentration 1mg/ml
Molecular Weight (kDa) 153
Research Area Adhesion, Cancer, Cell Signaling & Signal Transduction, Immunology, Stem Cell Biology
Notes Cytoplasmic antigen of mature B lymphocytes. >90% reactivity on peripheral B cells.

Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452.

Human B cell development. II. Subpopulations in the human fetus.

Europe PMC ID: 3871452


Add a reference

References: 2 entries

Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452.

Human B cell development. II. Subpopulations in the human fetus.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor